Stada reduces annual forecast

Stada says that it is unlikely to reach the same level of sales this year that it reached in 2008, even though fourth-quarter sales were higher than in the same period last year. However, a sales increase for the whole year, along with the target earnings before interest, tax, depreciation and amortisation of €250 million, are still possible, if they are adjusted for the effects from acquisitions and disposals as well as currency effects, it noted.

Stada says that it is unlikely to reach the same level of sales this year that it reached in 2008, even though fourth-quarter sales were higher than in the same period last year. However, a sales increase for the whole year, along with the target earnings before interest, tax, depreciation and amortisation of €250 million, are still possible, if they are adjusted for the effects from acquisitions and disposals as well as currency effects, it noted.

In the first nine months of this year, Stada's sales fell by 8% to €1.1 billion (+2% when adjusted for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip